Sponsor or institution

Clinical trials and research at BioNTech SE

• 25Clinical trials
• 38Countries

Newest trials

All recruiting trials (25)

• COVID-19 vaccine for children and adults at risk of severe disease

  This study tests an updated COVID-19 vaccine in people aged 5 to 64 with risk factors and adults 65+, to see how safe it is and how it behaves after vaccination.

  Recruiting at 14 sites Phase 3 BioNTech SE · Homestead, Florida and 13 other locations · NCT07798648

• Updated COVID-19 vaccine safety in healthy adults 18–64

  This study tests an updated COVID-19 vaccine and a booster vaccine in healthy adults to see how safe they are and how the body responds.

  Recruiting at 5 sites Phase 4 BioNTech SE · Walnut Creek, California and 4 other locations · NCT07730450

• RNA-based vaccine BNT168 safety and immune response in adults with or without HIV

  A first-in-human study tests whether the RNA vaccine BNT168 is safe and can trigger immune responses in adults both with and without HIV.

  Recruiting at 3 sites Phase 1 BioNTech SE · Houston, Texas and 3 other locations · NCT07698600

• BNT3214 for adults with advanced solid tumors

  This trial will test whether the experimental drug BNT3214 is safe and shows signs of benefit for adults whose advanced solid tumors have progressed after standard treatments.

  Recruiting at 6 sites Phase 1/2 BioNTech SE · Clayton and 15 other locations · NCT07455734

• Safety and blood activity of the antibody BNT351 in adults with and without HIV

  This study will test whether one dose of the antibody BNT351 is safe, how long it stays in the blood, and if it lowers HIV levels in adults with and without HIV.

  Recruiting at 5 sites Phase 1 BioNTech SE · Chicago, Illinois and 5 other locations · NCT07392372

• mRNA vaccine (BNT166a) for mpox and smallpox prevention in adults in Africa

  This tests whether two doses of the mRNA vaccine BNT166a are safe and produce an immune response in healthy adults in Africa, including people who have or have not had prior smallpox or mpox exposure.

  Recruiting at 6 sites Phase 2 BioNTech SE · Kinshasa and 5 other locations · NCT07379580

• BNT324 versus docetaxel for metastatic castration-resistant prostate cancer

  This trial will test whether BNT324, an antibody‑drug conjugate immunotherapy, works better than standard chemotherapy (docetaxel plus prednisone or prednisolone) for men with metastatic castration‑resistant prostate cancer who have had prior androgen‑receptor pathway inhibitors but no prior taxane chemotherapy for mCR

  Recruiting at 52 sites Phase 3 BioNTech SE · Santa Barbara, California and 51 other locations · NCT07365995

• Pumitamig with bevacizumab or temozolomide for adults with recurrent glioblastoma

  This test tries pumitamig, an investigational bispecific immunotherapy, alone or with bevacizumab or temozolomide in adults whose glioblastoma has returned after standard radiotherapy and temozolomide.

  Recruiting at 6 sites Phase 2 BioNTech SE · Beijing and 5 other locations · NCT07297212

• Pumitamig combined with chemotherapy for people with untreated metastatic pancreatic cancer

  This trial will test whether adding pumitamig (BNT327) to standard chemotherapy helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma who have not yet had systemic treatment.

  Recruiting at 14 sites Phase 2 BioNTech SE · Bedford Park and 23 other locations · NCT07255404

• Testing BNT329 for people with advanced solid tumors that express CA19-9.

  This will test whether the drug BNT329 is safe and might help people with advanced solid tumors that express the CA19-9 marker.

  Recruiting at 18 sites Phase 1/2 BioNTech SE · Denver, Colorado and 17 other locations · NCT07186842

• Pumitamig plus chemotherapy for metastatic triple-negative breast cancer

  This trial will test whether adding pumitamig to standard chemotherapy helps people with metastatic or inoperable triple-negative breast cancer who are not eligible for PD(L)1 combo therapy.

  Recruiting at 224 sites Phase 3 BioNTech SE · Springdale, Arkansas and 223 other locations · NCT07173751

• First-in-human dose escalation and expansion of BNT3212 alone or with BNT327 for adults with advanced solid tumors

  This trial will test BNT3212 by itself and together with pumitamig (BNT327) in adults with advanced solid tumors who have exhausted standard treatment options.

  Recruiting at 14 sites Phase 1/2 BioNTech SE · Adelaide and 16 other locations · NCT07147348

• PM8002 (BNT327) with chemotherapy in metastatic colorectal cancer

  This trial tests PM8002 (BNT327) combined with chemotherapy to see if it helps adults with first-line metastatic colorectal cancer that is not MSI-H/dMMR.

  Recruiting at 11 sites Phase 2 BioNTech SE · Beijing, Beijing Municipality and 10 other locations · NCT07133750

• BNT326 plus BNT327 combination for advanced non-small cell lung cancer

  This trial will test whether combining the investigational medicines BNT326 and BNT327 is safe and may help adults with advanced or metastatic non-small cell lung cancer, including some people who have had prior treatment and some who have not.

  Recruiting at 86 sites Phase 1/2 BioNTech SE · Los Angeles, California and 85 other locations · NCT07111520

• BNT314 with BNT327 plus chemotherapy for advanced colorectal cancer

  This will test whether adding BNT314 and the immunotherapy BNT327 to standard chemotherapy helps people with metastatic, microsatellite-stable (MSS/pMMR) colorectal cancer.

  Recruiting at 14 sites Phase 1/2 BioNTech SE · New Haven, Connecticut and 13 other locations · NCT07079631

• BNT326 alone or with other investigational drugs for advanced solid tumors

  This study will test whether BNT326, given alone or with other investigational medicines such as pumitamig, is safe and may help adults with advanced solid tumors that have progressed after prior treatments.

  Recruiting at 70 sites Phase 1/2 BioNTech SE · Phoenix, Arizona and 76 other locations · NCT07070232

• Investigating a new combination therapy for advanced lung cancer

  This study is testing a new combination treatment for advanced lung cancer to see if it’s safe and effective for patients.

  Recruiting at 91 sites Phase 1/2 BioNTech SE · Phoenix, Arizona and 90 other locations · NCT06892548

• Investigational therapy for advanced non-small cell lung cancer combined with chemotherapy

  This study is testing a new treatment that combines an experimental drug with chemotherapy to see if it helps people with advanced lung cancer who haven't responded to previous treatments.

  Recruiting at 29 sites Phase 2 BioNTech SE · Birmingham, Alabama and 29 other locations · NCT06841055

• Finding the best dose of BNT323 and BNT327 for advanced breast cancer

  This study is testing the best dose of a new combination treatment for advanced breast cancer to see how well it works and if it's safe for patients.

  Recruiting at 84 sites Phase 1/2 BioNTech SE · Beverly Hills, California and 83 other locations · NCT06827236

• Investigational therapy for advanced solid tumors

  This study is testing a new therapy for people with advanced solid tumors to see if it's safe and how well it works at different doses.

  Recruiting at 5 sites Phase 1/2 BioNTech SE · Louisville, Kentucky and 10 other locations · NCT06750185

• Investigating BNT327 with chemotherapy for untreated small-cell lung cancer

  This study is testing whether a new treatment called BNT327, combined with standard chemotherapy, can help people with untreated extensive-stage small-cell lung cancer feel better compared to another treatment option.

  Recruiting at 188 sites Phase 3 BioNTech SE · Tucson, Arizona and 224 other locations · NCT06712355

• Combining BNT327 with chemotherapy for treating lung cancer

  This study is testing if a new treatment called BNT327, when combined with standard chemotherapy, can help people with non-small cell lung cancer feel better and improve their outcomes.

  Recruiting at 360 sites Phase 2/3 BioNTech SE · Birmingham, Alabama and 365 other locations · NCT06712316

• Treatment of recurring uterine (endometrial) cancer with the investigational drug BNT323 or chemotherapy

  This study tests whether the investigational drug BNT323 works better than single-agent chemotherapy for people with recurrent HER2-expressing endometrial cancer who have had platinum chemotherapy and immune checkpoint inhibitors, and also examines BNT323 alone for tumors with very high HER2 expression.

  Recruiting at 214 sites Phase 3 BioNTech SE · Los Angeles, California and 213 other locations · NCT06340568

• Treatment of advanced solid tumors with PM8002

  This study is testing a new treatment called PM8002 to see if it can help adults with advanced solid tumors by targeting specific proteins that may help fight their cancer.

  Recruiting at 48 sites Phase 1/2 BioNTech SE · Baoji and 47 other locations · NCT05918445

• Evaluating a new cancer vaccine for advanced non-small cell lung cancer

  This study is testing a new cancer vaccine to see if it can help people with advanced non-small cell lung cancer feel better, either on its own or with other treatments.

  Recruiting at 41 sites Phase 1 BioNTech SE · Lexington, Kentucky and 44 other locations · NCT05142189

Quick answers

How many clinical trials run by BioNTech SE are recruiting right now?

25, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 38 countries. The most sites are in United States (18 trials), Australia (16 trials), China (15 trials), United Kingdom (13 trials), Spain (12 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 10, Phase 3: 5, Phase 2: 5, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →